832 related articles for article (PubMed ID: 16229851)
1. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
[TBL] [Abstract][Full Text] [Related]
3. Macrophage paraoxonase 1 (PON1) binding sites.
Efrat M; Aviram M
Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
[TBL] [Abstract][Full Text] [Related]
6. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities.
Rock W; Rosenblat M; Miller-Lotan R; Levy AP; Elias M; Aviram M
J Agric Food Chem; 2008 Sep; 56(18):8704-13. PubMed ID: 18759451
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
Li C; Gu Q
Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
[TBL] [Abstract][Full Text] [Related]
8. HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: in vivo and in vitro studies.
Rosenblat M; Volkova N; Aviram M
Biofactors; 2014; 40(5):536-45. PubMed ID: 25230879
[TBL] [Abstract][Full Text] [Related]
9. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
10. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties.
Rozenberg O; Shiner M; Aviram M; Hayek T
Free Radic Biol Med; 2008 Jun; 44(11):1951-9. PubMed ID: 18358245
[TBL] [Abstract][Full Text] [Related]
12. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity.
Rozenberg O; Aviram M
Biochem Biophys Res Commun; 2006 Dec; 351(2):492-8. PubMed ID: 17070779
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonases role in the prevention of cardiovascular diseases.
Rosenblat M; Aviram M
Biofactors; 2009; 35(1):98-104. PubMed ID: 19319852
[TBL] [Abstract][Full Text] [Related]
14. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
[TBL] [Abstract][Full Text] [Related]
15. HDL--associated paraoxonase 1 (PON1) and dietary antioxidants attenuate lipoprotein oxidation, macrophage foam cells formation and atherosclerosis development.
Aviram M
Pathophysiol Haemost Thromb; 2006; 35(1-2):146-51. PubMed ID: 16855361
[No Abstract] [Full Text] [Related]
16. Variation in paraoxonase-1 activity and atherosclerosis.
Soran H; Younis NN; Charlton-Menys V; Durrington P
Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
[TBL] [Abstract][Full Text] [Related]
17. Oxidative status and serum PON1 activity in beta-thalassemia minor.
Selek S; Aslan M; Horoz M; Gur M; Erel O
Clin Biochem; 2007 Mar; 40(5-6):287-91. PubMed ID: 17296173
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL
Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466
[TBL] [Abstract][Full Text] [Related]
19. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats.
Trudel K; Sinnett D; James RW; Delvin E; Amre D; Seidman E; Levy E
J Cell Biochem; 2005 Oct; 96(2):404-11. PubMed ID: 16052486
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids.
Efrat M; Aviram M
Adv Exp Med Biol; 2010; 660():153-66. PubMed ID: 20221878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
